Nuvectis Pharma, Inc. Stock-Based Compensation
Nuvectis Pharma, Inc. (NVCT) reported Stock-Based Compensation of $3.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-04
- Nuvectis Pharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.71M, a 1.27% decline year-over-year.
- Nuvectis Pharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.85M, a 35.23% increase year-over-year.
- Nuvectis Pharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.48M, a 29.36% increase year-over-year.
- Nuvectis Pharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.46M, a 25.71% increase year-over-year.
- Nuvectis Pharma, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $6.03M, a 24.17% increase from fiscal 2024.
- Nuvectis Pharma, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $4.86M, a 3.25% increase from fiscal 2023.
- Nuvectis Pharma, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $4.71M, a 175.63% increase from fiscal 2022.
- Nuvectis Pharma, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $1.71M, a 9.78% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $3.56M 10-Q · filed 2026-08-04 | $5.04M derived: sum of 3 quarters · filed 2026-08-04 | $6.49M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $1.85M 10-Q · filed 2026-05-05 | $3.33M derived: sum of 2 quarters · filed 2026-05-05 | $4.78M derived: sum of 3 quarters · filed 2026-05-05 | $6.51M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $2.93M derived: sum of 2 quarters · filed 2026-02-11 | $4.66M derived: sum of 3 quarters · filed 2026-08-04 | $6.03M 10-K · filed 2026-02-11 |
| 2025-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.19M derived: sum of 2 quarters · filed 2026-08-04 | $4.56M 10-Q · filed 2025-11-04 | $5.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $3.10M 10-Q · filed 2026-08-04 | $4.24M derived: sum of 3 quarters · filed 2026-08-04 | $5.40M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $1.37M 10-Q · filed 2026-05-05 | $2.51M derived: sum of 2 quarters · filed 2026-05-05 | $3.67M derived: sum of 3 quarters · filed 2026-05-05 | $4.93M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $2.30M derived: sum of 2 quarters · filed 2026-02-11 | $3.56M derived: sum of 3 quarters · filed 2026-02-11 | $4.86M 10-K · filed 2026-02-11 |
| 2024-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.42M derived: sum of 2 quarters · filed 2025-11-04 | $3.72M 10-Q · filed 2025-11-04 | $4.94M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.56M 10-Q · filed 2025-08-05 | $3.78M derived: sum of 3 quarters · filed 2025-08-05 | $4.91M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $1.30M 10-Q · filed 2025-05-06 | $2.52M derived: sum of 2 quarters · filed 2025-05-06 | $3.65M derived: sum of 3 quarters · filed 2025-05-06 | $4.60M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $2.35M derived: sum of 2 quarters · filed 2025-02-25 | $3.30M derived: sum of 3 quarters · filed 2025-02-25 | $4.71M 10-K · filed 2025-02-25 |
| 2023-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $2.08M derived: sum of 2 quarters · filed 2024-11-05 | $3.48M 10-Q · filed 2024-11-05 | $3.97M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $950.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $2.35M 10-Q · filed 2024-08-06 | $2.83M derived: sum of 3 quarters · filed 2024-08-06 | $3.39M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.40M 10-Q · filed 2024-05-07 | $1.88M derived: sum of 2 quarters · filed 2024-05-07 | $2.44M derived: sum of 3 quarters · filed 2024-05-07 | $2.95M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $482.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $1.04M derived: sum of 2 quarters · filed 2024-03-05 | $1.55M derived: sum of 3 quarters · filed 2024-03-05 | $1.71M 10-K · filed 2024-03-05 |
| 2022-09-30 | $559.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.07M derived: sum of 2 quarters · filed 2023-11-08 | $1.23M 10-Q · filed 2023-11-08 | $1.41M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $510.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $666.00K 10-Q · filed 2023-08-09 | $851.00K derived: sum of 3 quarters · filed 2023-08-09 | $987.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $156.00K 10-Q · filed 2023-05-10 | $341.00K derived: sum of 2 quarters · filed 2023-05-10 | $477.00K derived: sum of 3 quarters · filed 2023-05-10 | |
| 2021-12-31 | $185.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $321.00K derived: sum of 2 quarters · filed 2023-03-08 | $1.89M 10-K · filed 2023-03-08 | |
| 2021-09-30 | $136.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.71M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $1.57M 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |